411 papers
This study identifies nine cases where LINE-1 retrotransposition insertions cause MET exon 14 skipping in cancer, establishing this mechanism as a recurrent and clinically actionable driver of oncogenic signaling.
This study identifies the tRNA-Arg-TCT-4-1 isodecoder as a critical oncogenic driver in multiple cancer types and demonstrates that its specific inhibition via antisense oligonucleotides suppresses tumor growth and extends survival by inducing codon-biased remodeling of mRNA translation.
This study establishes a human model of CEBPA-mutant acute myeloid leukemia using CRISPR-edited hematopoietic stem cells, demonstrating that the leukemic CEBPA-p30 isoform drives transformation—accelerated by TET2 or WT1 loss—and reveals that targeting the resulting cholesterol biosynthesis dependency offers a promising therapeutic strategy, particularly for patients with poor-outcome co-mutations.
The study demonstrates that the novel CDK12/13 inhibitor CTX-439 suppresses tumor growth by downregulating DNA damage repair genes and shifting cell survival dependency to BCL-2 and BCL-xL, thereby establishing a synergistic combination therapy with BCL-2 family inhibitors to overcome resistance and enhance anti-tumor efficacy.
This study reveals that the mis-segregation of extrachromosomal DNA (ecDNA) into micronuclei restricts oncogenic transcription and cellular fitness, thereby linking higher frequencies of ecDNA-positive micronuclei to improved survival outcomes in neuroblastoma patients.
Using super-resolution microscopy, this study reveals that estrogen receptor activity dynamically regulates the structural conformation of H3K27ac-marked chromatin, transitioning between open, active states and compact, inactive states, thereby challenging the notion that this epigenetic mark alone is sufficient for enhancer activation and offering new insights into endocrine therapy resistance in breast cancer.
This study reveals that EZH2 inhibition in triple-negative breast cancer triggers an integrated stress response that drives glutaminolysis to sustain cell survival, thereby identifying glutaminase inhibition as a critical synergistic strategy to overcome resistance and enhance the efficacy of EZH2-targeted therapies.
This study identifies TPM3 as a HIF-1-regulated, hypoxia-induced effector in triple-negative breast cancer that drives cytoskeletal dynamics, cell motility, and invasion while facilitating intercellular communication via extracellular vesicles, thereby representing a promising therapeutic target to enhance treatment efficacy.
The study demonstrates that the SF3B1 inhibitor pladienolide B counteracts platinum salt resistance in Non-Small Cell Lung Cancer by inducing genomic instability, impairing DNA damage repair through altered splicing (particularly of MLH3), and suppressing key signaling pathways, thereby offering a promising therapeutic strategy for platinum-resistant tumors.
This study demonstrates that an unsupervised 1D convolutional autoencoder trained on healthy CEST MRI Z-spectra can effectively and robustly delineate glioblastoma in preclinical models by detecting metabolic anomalies, outperforming traditional baseline methods and maintaining accuracy even with accelerated, under-sampled data acquisition.
This study establishes a biopsy-compatible ex vivo drug sensitivity testing platform for rare solid tumors that successfully identifies actionable drug responses and demonstrates a significant correlation between high in vitro sensitivity and improved clinical outcomes, supporting its use as a complementary tool in precision oncology.
This study analyzes 3,302 single-cell transcriptomes to distinguish true circulating tumor cells (CTCs) from blood contaminants, identifies novel markers for epithelial and mesenchymal CTC subtypes, and introduces CTCeek, a web-based tool for the automated annotation of bona fide CTCs.
This study employs an integrative systems-level transcriptomic analysis to reveal that gastric cancer progression is driven by coordinated chromatin-level developmental reprogramming, characterized by the upregulation of HOX genes and loss of gastric differentiation markers, alongside FGFR-mediated oncogenic signaling and stage-dependent metabolic disruption.
This study utilizes integrative transcriptomics and mutational analysis to identify POSTN and CAP1-derived neoantigen peptides and stratify triple-negative breast cancer patients into immune subtypes, proposing a vaccine strategy to convert immune-cold tumors into immune-enriched phenotypes while identifying hub genes as prognostic biomarkers.
This study utilizes a cross-species comparative oncology approach and modified MNase ChIP to demonstrate that while both PAX3::FOXO1 and PAX7::FOXO1 fusion oncoproteins function as pioneer factors capable of binding nucleosomal DNA in rhabdomyosarcoma, they engage distinct nucleosomal targets with different motif preferences and histone mark co-localization patterns, providing a mechanistic explanation for their divergent clinical outcomes.
This study presents a comprehensive multiomic analysis of human and canine soft-tissue sarcomas, revealing extensive molecular homology between species, redefining fibrosarcoma and myxofibrosarcoma as a molecular continuum with clinically relevant subgroups, and validating the dog as a valuable translational model for developing targeted therapies.
This study identifies small nucleolar RNAs (snoRNAs) enriched in extracellular vesicles as promising, minimally invasive liquid biomarkers for detecting radiation-induced senescence in glioblastoma, offering a potential companion diagnostic for senotherapeutic strategies.
This study establishes a comprehensive biobank of polyclonal and single-cell-derived clonal organoids from normal tissue, Barrett's esophagus, and esophageal adenocarcinoma that faithfully recapitulate disease heterogeneity and molecular features, enabling the isolation of high-risk subclones and the evaluation of diverse responses to cancer therapies.
This study demonstrates that biologically relevant vitamin D deficiency impairs prostate epithelial differentiation and enhances cancer aggressiveness by disrupting androgen signaling and key cancer-related pathways in both ex vivo and in vivo models, thereby supporting the potential of vitamin D supplementation to mitigate prostate cancer risk.
This study reports the first successful in vivo selection of DNA aptamer-drug conjugates (ApDCs) using a massive library and an orthotopic patient-derived xenograft model to overcome the blood-brain barrier and intratumoral heterogeneity challenges in treating glioblastoma.